Evaluation of the MAIIA dipstick test to detect recombinant human erythropoietin in plasma

Michael Ashenden, Ken Sharpe, Andrew Garnham, Christopher J. Gore

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Recently a novel technology, referred to as the 'EPO WGA MAIIA' test, has been developed by Swedish researchers to discriminate between endogenous and recombinant human erythropoietin. In contrast to existing electrophoretic methods that are used by antidoping laboratories, this dipstick-based technique is simple and fast. Moreover it can be applied to either blood or urine specimens. These characteristics could prove advantageous if the test were adopted by antidoping authorities to determine blood doping in sport. We evaluated the sensitivity of EPO WGA MAIIA to detect the presence of recombinant human erythropoietin (rhEPO) in some archived plasma specimens which had been collected from healthy, active subjects either 72. h or 96. h after a 'microdose' intravenous injection of rhEPO. Under these conditions the test had modest sensitivity to discriminate rhEPO, with only two of nine subjects exceeding an arbitrary cut-off 3.09 SDs beyond the expected population mean. Sensitivity was improved to five out of six subjects if positivity was assessed according to the subject's own previous values rather than a population-based threshold. We conclude that, with further refinement, the dipstick test may supplement existing antidoping tests.

Original languageEnglish
Pages (from-to)123-128
Number of pages6
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume67-68
DOIs
Publication statusPublished - Aug 2012
Externally publishedYes

Fingerprint

Erythropoietin
Doping in Sports
Plasmas
Blood
Sports
Intravenous Injections
Population
Healthy Volunteers
Doping (additives)
Research Personnel
Urine
Technology

Cite this

Ashenden, Michael ; Sharpe, Ken ; Garnham, Andrew ; Gore, Christopher J. / Evaluation of the MAIIA dipstick test to detect recombinant human erythropoietin in plasma. In: Journal of Pharmaceutical and Biomedical Analysis. 2012 ; Vol. 67-68. pp. 123-128.
@article{ebaca8bd75f1481ba69882ef7c7f949e,
title = "Evaluation of the MAIIA dipstick test to detect recombinant human erythropoietin in plasma",
abstract = "Recently a novel technology, referred to as the 'EPO WGA MAIIA' test, has been developed by Swedish researchers to discriminate between endogenous and recombinant human erythropoietin. In contrast to existing electrophoretic methods that are used by antidoping laboratories, this dipstick-based technique is simple and fast. Moreover it can be applied to either blood or urine specimens. These characteristics could prove advantageous if the test were adopted by antidoping authorities to determine blood doping in sport. We evaluated the sensitivity of EPO WGA MAIIA to detect the presence of recombinant human erythropoietin (rhEPO) in some archived plasma specimens which had been collected from healthy, active subjects either 72. h or 96. h after a 'microdose' intravenous injection of rhEPO. Under these conditions the test had modest sensitivity to discriminate rhEPO, with only two of nine subjects exceeding an arbitrary cut-off 3.09 SDs beyond the expected population mean. Sensitivity was improved to five out of six subjects if positivity was assessed according to the subject's own previous values rather than a population-based threshold. We conclude that, with further refinement, the dipstick test may supplement existing antidoping tests.",
keywords = "Blood doping, MAIIA, Recombinant human erythropoietin",
author = "Michael Ashenden and Ken Sharpe and Andrew Garnham and Gore, {Christopher J.}",
year = "2012",
month = "8",
doi = "10.1016/j.jpba.2012.04.025",
language = "English",
volume = "67-68",
pages = "123--128",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",

}

Evaluation of the MAIIA dipstick test to detect recombinant human erythropoietin in plasma. / Ashenden, Michael; Sharpe, Ken; Garnham, Andrew; Gore, Christopher J.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 67-68, 08.2012, p. 123-128.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of the MAIIA dipstick test to detect recombinant human erythropoietin in plasma

AU - Ashenden, Michael

AU - Sharpe, Ken

AU - Garnham, Andrew

AU - Gore, Christopher J.

PY - 2012/8

Y1 - 2012/8

N2 - Recently a novel technology, referred to as the 'EPO WGA MAIIA' test, has been developed by Swedish researchers to discriminate between endogenous and recombinant human erythropoietin. In contrast to existing electrophoretic methods that are used by antidoping laboratories, this dipstick-based technique is simple and fast. Moreover it can be applied to either blood or urine specimens. These characteristics could prove advantageous if the test were adopted by antidoping authorities to determine blood doping in sport. We evaluated the sensitivity of EPO WGA MAIIA to detect the presence of recombinant human erythropoietin (rhEPO) in some archived plasma specimens which had been collected from healthy, active subjects either 72. h or 96. h after a 'microdose' intravenous injection of rhEPO. Under these conditions the test had modest sensitivity to discriminate rhEPO, with only two of nine subjects exceeding an arbitrary cut-off 3.09 SDs beyond the expected population mean. Sensitivity was improved to five out of six subjects if positivity was assessed according to the subject's own previous values rather than a population-based threshold. We conclude that, with further refinement, the dipstick test may supplement existing antidoping tests.

AB - Recently a novel technology, referred to as the 'EPO WGA MAIIA' test, has been developed by Swedish researchers to discriminate between endogenous and recombinant human erythropoietin. In contrast to existing electrophoretic methods that are used by antidoping laboratories, this dipstick-based technique is simple and fast. Moreover it can be applied to either blood or urine specimens. These characteristics could prove advantageous if the test were adopted by antidoping authorities to determine blood doping in sport. We evaluated the sensitivity of EPO WGA MAIIA to detect the presence of recombinant human erythropoietin (rhEPO) in some archived plasma specimens which had been collected from healthy, active subjects either 72. h or 96. h after a 'microdose' intravenous injection of rhEPO. Under these conditions the test had modest sensitivity to discriminate rhEPO, with only two of nine subjects exceeding an arbitrary cut-off 3.09 SDs beyond the expected population mean. Sensitivity was improved to five out of six subjects if positivity was assessed according to the subject's own previous values rather than a population-based threshold. We conclude that, with further refinement, the dipstick test may supplement existing antidoping tests.

KW - Blood doping

KW - MAIIA

KW - Recombinant human erythropoietin

UR - http://www.scopus.com/inward/record.url?scp=84862132396&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2012.04.025

DO - 10.1016/j.jpba.2012.04.025

M3 - Article

VL - 67-68

SP - 123

EP - 128

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

ER -